{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:46:05Z","timestamp":1792809965916,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,21]]},"DOI":"10.7759\/cureus.45719","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T19:18:53Z","timestamp":1695323933000},"source":"Crossref","is-referenced-by-count":10,"title":["The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Snaiha I","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle V","family":"Terre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutvi","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshvi V","family":"Shanghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Ghouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binish A","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri N","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christena","family":"Satram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna A","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle K","family":"Bayoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger RH","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021, 11:263-76. 10.21037\/cdt-20-302","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref4","article-title":"Congestive Heart Failure","author":"Malik A","year":"2022","unstructured":"Malik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/echo.15205","article-title":"Right ventricular free wall strain in acutely decompensated heart failure patients with ischemic and non-ischemic cardiomyopathy","volume":"38","author":"Miric D","year":"2021","unstructured":"Miric D, Barac A, Capkun V, Bakovic D. Right ventricular free wall strain in acutely decompensated heart failure patients with ischemic and non-ischemic cardiomyopathy. Echocardiography. 2021, 38:1747-53. 10.1111\/echo.15205","journal-title":"Echocardiography"},{"key":"ref7","article-title":"Left Ventricular Ejection Fraction","author":"Kosaraju A","year":"2022","unstructured":"Kosaraju A, Goyal A, Grigorova Y, Makaryus AN. Left Ventricular Ejection Fraction. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3920195","article-title":"A review of the molecular mechanisms underlying the development and progression of cardiac remodeling","volume":"2017","author":"Schirone L","year":"2017","unstructured":"Schirone L, Forte M, Palmerio S, et al.. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017, 2017:3920195. 10.1155\/2017\/3920195","journal-title":"Oxid Med Cell Longev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00259.2019","article-title":"Guidelines for evaluating myocardial cell death","volume":"317","author":"Mishra PK","year":"2019","unstructured":"Mishra PK, Adameova A, Hill JA, et al.. Guidelines for evaluating myocardial cell death. Am J Physiol Heart Circ Physiol. 2019, 317:H891-922. 10.1152\/ajpheart.00259.2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09806-0","article-title":"Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies","volume":"24","author":"Ge Z","year":"2019","unstructured":"Ge Z, Li A, McNamara J, Dos Remedios C, Lal S. Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies. Heart Fail Rev. 2019, 24:743-58. 10.1007\/s10741-019-09806-0","journal-title":"Heart Fail Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(65)90211-1","article-title":"Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure","volume":"39","author":"Chidsey CA","year":"1965","unstructured":"Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965, 39:442-51. 10.1016\/0002-9343(65)90211-1","journal-title":"Am J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee J","year":"2017","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017, 14:30-8. 10.1038\/nrcardio.2016.163","journal-title":"Nat Rev Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow GC","year":"2011","unstructured":"Fonarow GC, Yancy CW, Hernandez AF, Peterson ED, Spertus JA, Heidenreich PA. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J. 2011, 161:1024-30.e3. 10.1016\/j.ahj.2011.01.027","journal-title":"Am Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2018.08.003","article-title":"Heart failure with reduced ejection fraction in women: epidemiology, outcomes, and treatment","volume":"15","author":"Mentzer G","year":"2019","unstructured":"Mentzer G, Hsich EM. Heart failure with reduced ejection fraction in women: epidemiology, outcomes, and treatment. Heart Fail Clin. 2019, 15:19-27. 10.1016\/j.hfc.2018.08.003","journal-title":"Heart Fail Clin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah KS","year":"2017","unstructured":"Shah KS, Xu H, Matsouaka RA, et al.. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017, 70:2476-86. 10.1016\/j.jacc.2017.08.074","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133182","article-title":"Renin activity in heart failure with reduced systolic function-new insights","volume":"20","author":"Sullivan RD","year":"2019","unstructured":"Sullivan RD, Mehta RM, Tripathi R, Reed GL, Gladysheva IP. Renin activity in heart failure with reduced systolic function-new insights. Int J Mol Sci. 2019, 20:3182. 10.3390\/ijms20133182","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe M","year":"2016","unstructured":"Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016, 130:57-77. 10.1042\/CS20150469","journal-title":"Clin Sci (Lond)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa063904","article-title":"Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development","volume":"355","author":"Murad F","year":"2006","unstructured":"Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006, 355:2003-11. 10.1056\/NEJMsa063904","journal-title":"N Engl J Med"},{"key":"ref19","article-title":"Physiology, Frank Starling Law","author":"Delicce AV","year":"2022","unstructured":"Delicce AV, Makaryus AN. Physiology, Frank Starling Law. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90617-v","article-title":"Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension","volume":"19","author":"Ganau A","year":"1992","unstructured":"Ganau A, Devereux RB, Roman MJ, et al.. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992, 19:1550-8. 10.1016\/0735-1097(92)90617-v","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with\u00a0reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene SJ","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, et al.. Medical therapy for heart failure with\u00a0reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018, 72:351-66. 10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009889.pub2","article-title":"Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction","volume":"2015","author":"Driscoll A","year":"2015","unstructured":"Driscoll A, Currey J, Tonkin A, Krum H. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev. 2015, 2015:CD009889. 10.1002\/14651858.CD009889.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd8090101","article-title":"The use of \u03b2-blockers in heart failure with reduced ejection fraction","volume":"8","author":"Masarone D","year":"2021","unstructured":"Masarone D, Martucci ML, Errigo V, Pacileo G. The use of \u03b2-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis. 2021, 8:101. 10.3390\/jcdd8090101","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Heart rate and rhythm and the benefit\u00a0of\u00a0beta-blockers in patients\u00a0with\u00a0heart failure","volume":"69","author":"Kotecha D","year":"2017","unstructured":"Kotecha D, Flather MD, Altman DG, et al.. Heart rate and rhythm and the benefit\u00a0of\u00a0beta-blockers in patients\u00a0with\u00a0heart failure. J Am Coll Cardiol. 2017, 69:2885-96. 10.1016\/j.jacc.2017.04.001","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2174\/157016112799304969","article-title":"Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists","volume":"10","author":"Ronconi V","year":"2012","unstructured":"Ronconi V, Turchi F, Appolloni G, di Tizio V, Boscaro M, Giacchetti G. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr Vasc Pharmacol. 2012, 10:238-46. 10.2174\/157016112799304969","journal-title":"Curr Vasc Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart\u00a0failure with reduced ejection fraction","volume":"8","author":"Serenelli M","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, et al.. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart\u00a0failure with reduced ejection fraction. JACC Heart Fail. 2020, 8:188-98. 10.1016\/j.jchf.2019.09.011","journal-title":"JACC Heart Fail"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0425-x","article-title":"Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis","volume":"16","author":"Berbenetz NM","year":"2016","unstructured":"Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016, 16:246. 10.1186\/s12872-016-0425-x","journal-title":"BMC Cardiovasc Disord"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/2040622318784556","article-title":"The therapeutic role of ivabradine in heart failure","volume":"9","author":"Badu-Boateng C","year":"2018","unstructured":"Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018, 9:199-207. 10.1177\/2040622318784556","journal-title":"Ther Adv Chronic Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.07.001","article-title":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"22","year":"2016","unstructured":"2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure. an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2016, 22:659-69. 10.1016\/j.cardfail.2016.07.001","journal-title":"J Card Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612873","article-title":"Ivabradine for treatment of heart failure","volume":"18","author":"Bocchi EA","year":"2019","unstructured":"Bocchi EA, Salemi VM. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019, 18:393-402. 10.1080\/14740338.2019.1612873","journal-title":"Expert Opin Drug Saf"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.05.002","article-title":"Efficacy of sacubitril\/valsartan relative to\u00a0a prior decompensation: the PARADIGM-HF trial","volume":"4","author":"Solomon SD","year":"2016","unstructured":"Solomon SD, Claggett B, Packer M, et al.. Efficacy of sacubitril\/valsartan relative to\u00a0a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016, 4:816-22. 10.1016\/j.jchf.2016.05.002","journal-title":"JACC Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers SA","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016, 133:1115-24. 10.1161\/CIRCULATIONAHA.115.018622","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer AJ","year":"2019","unstructured":"Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril\/valsartan for heart failure. Heart Fail Rev. 2019, 24:167-76. 10.1007\/s10741-018-9757-1","journal-title":"Heart Fail Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal D","year":"2021","unstructured":"Pascual-Figal D, Bay\u00e9s-Genis A, Beltr\u00e1n-Troncoso P, et al.. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review. Front Cardiovasc Med. 2021, 8:754499. 10.3389\/fcvm.2021.754499","journal-title":"Front Cardiovasc Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai AS","year":"2015","unstructured":"Desai AS, McMurray JJ, Packer M, et al.. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015, 36:1990-7. 10.1093\/eurheartj\/ehv186","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego C","year":"2018","unstructured":"de Diego C, Gonz\u00e1lez-Torres L, N\u00fa\u00f1ez JM, et al.. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018, 15:395-402. 10.1016\/j.hrthm.2017.11.012","journal-title":"Heart Rhythm"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer M","year":"2018","unstructured":"Packer M, Claggett B, Lefkowitz MP, McMurray JJ, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018, 6:547-54. 10.1016\/S2213-8587(18)30100-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman K","year":"2018","unstructured":"Damman K, Gori M, Claggett B, et al.. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018, 6:489-98. 10.1016\/j.jchf.2018.02.004","journal-title":"JACC Heart Fail"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen AJ","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015, 75:33-59. 10.1007\/s40265-014-0337-y","journal-title":"Drugs"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie MR","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020, 17:761-72. 10.1038\/s41569-020-0406-8","journal-title":"Nat Rev Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01989-z","article-title":"Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review","volume":"39","author":"Rao S","year":"2022","unstructured":"Rao S. Use of sodium-glucose cotransporter-2 inhibitors in clinical practice for heart failure prevention and treatment: beyond type 2 diabetes. A narrative review. Adv Ther. 2022, 39:845-61. 10.1007\/s12325-021-01989-z","journal-title":"Adv Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni D","year":"2022","unstructured":"Tomasoni D, Fonarow GC, Adamo M, et al.. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022, 24:431-41. 10.1002\/ejhf.2397","journal-title":"Eur J Heart Fail"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2018.04.011","article-title":"Physiological activation and deactivation of soluble guanylate cyclase","volume":"77","author":"Horst BG","year":"2018","unstructured":"Horst BG, Marletta MA. Physiological activation and deactivation of soluble guanylate cyclase. Nitric Oxide. 2018, 77:65-74. 10.1016\/j.niox.2018.04.011","journal-title":"Nitric Oxide"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade M","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, et al.. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015, 314:2251-62. 10.1001\/jama.2015.15734","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik FI","year":"2011","unstructured":"Malik FI, Hartman JJ, Elias KA, et al.. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011, 331:1439-43. 10.1126\/science.1200113","journal-title":"Science"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink JR","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJ, et al.. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016, 388:2895-903. 10.1016\/S0140-6736(16)32049-9","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.051","article-title":"Cardiac calcitropes, myotropes, and\u00a0mitotropes: JACC review topic of the week","volume":"73","author":"Psotka MA","year":"2019","unstructured":"Psotka MA, Gottlieb SS, Francis GS, et al.. Cardiac calcitropes, myotropes, and\u00a0mitotropes: JACC review topic of the week. J Am Coll Cardiol. 2019, 73:2345-53. 10.1016\/j.jacc.2019.02.051","journal-title":"J Am Coll Cardiol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.928","article-title":"Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort","volume":"20","author":"Biering-S\u00f8rensen T","year":"2018","unstructured":"Biering-S\u00f8rensen T, Querejeta Roca G, Hegde SM, et al.. Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. Eur J Heart Fail. 2018, 20:1106-14. 10.1002\/ejhf.928","journal-title":"Eur J Heart Fail"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1725","article-title":"Systolic time intervals in patients with heart failure: time to teach new dogs old tricks","volume":"22","author":"Njoroge JN","year":"2020","unstructured":"Njoroge JN, Teerlink JR. Systolic time intervals in patients with heart failure: time to teach new dogs old tricks. Eur J Heart Fail. 2020, 22:1183-5. 10.1002\/ejhf.1725","journal-title":"Eur J Heart Fail"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1659","article-title":"Association between systolic ejection time and outcomes in heart failure by ejection fraction","volume":"22","author":"Patel PA","year":"2020","unstructured":"Patel PA, Ambrosy AP, Phelan M, et al.. Association between systolic ejection time and outcomes in heart failure by ejection fraction. Eur J Heart Fail. 2020, 22:1174-82. 10.1002\/ejhf.1659","journal-title":"Eur J Heart Fail"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart\u00a0failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink JR","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al.. Omecamtiv mecarbil in chronic heart\u00a0failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020, 8:329-40. 10.1016\/j.jchf.2019.12.001","journal-title":"JACC Heart Fail"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer DG","year":"2010","unstructured":"Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010, 56:392-406. 10.1016\/j.jacc.2010.05.011","journal-title":"J Am Coll Cardiol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.02.007","article-title":"Natriuretic peptides as biomarkers of treatment response in clinical trials of\u00a0heart failure","volume":"6","author":"Vaduganathan M","year":"2018","unstructured":"Vaduganathan M, Claggett B, Packer M, et al.. Natriuretic peptides as biomarkers of treatment response in clinical trials of\u00a0heart failure. JACC Heart Fail. 2018, 6:564-9. 10.1016\/j.jchf.2018.02.007","journal-title":"JACC Heart Fail"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis GD","year":"2022","unstructured":"Lewis GD, Voors AA, Cohen-Solal A, et al.. Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial. JAMA. 2022, 328:259-69. 10.1001\/jama.2022.11016","journal-title":"JAMA"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.4027","article-title":"Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial","volume":"7","author":"Felker GM","year":"2022","unstructured":"Felker GM, Solomon SD, Claggett B, et al.. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 2022, 7:26-34. 10.1001\/jamacardio.2021.4027","journal-title":"JAMA Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-017-9662-z","article-title":"Exercise therapy and autonomic function in heart failure patients: a systematic review and meta-analysis","volume":"23","author":"Pearson MJ","year":"2018","unstructured":"Pearson MJ, Smart NA. Exercise therapy and autonomic function in heart failure patients: a systematic review and meta-analysis. Heart Fail Rev. 2018, 23:91-108. 10.1007\/s10741-017-9662-z","journal-title":"Heart Fail Rev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1249\/JSR.0000000000000869","article-title":"Physical activity in the treatment and prevention of heart failure: an update","volume":"20","author":"LaMonte MJ","year":"2021","unstructured":"LaMonte MJ, Eaton CB. Physical activity in the treatment and prevention of heart failure: an update. Curr Sports Med Rep. 2021, 20:410-7. 10.1249\/JSR.0000000000000869","journal-title":"Curr Sports Med Rep"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-019-00428-z","article-title":"Exercise in heart failure-what is the optimal dose to improve pathophysiology and exercise capacity?","volume":"16","author":"Schindler MJ","year":"2019","unstructured":"Schindler MJ, Adams V, Halle M. Exercise in heart failure-what is the optimal dose to improve pathophysiology and exercise capacity?. Curr Heart Fail Rep. 2019, 16:98-107. 10.1007\/s11897-019-00428-z","journal-title":"Curr Heart Fail Rep"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(01)01795-8","article-title":"Physical training modulates proinflammatory cytokines and the soluble Fas\/soluble Fas ligand system in patients with chronic heart failure","volume":"39","author":"Adamopoulos S","year":"2002","unstructured":"Adamopoulos S, Parissis J, Karatzas D, et al.. Physical training modulates proinflammatory cytokines and the soluble Fas\/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002, 39:653-63. 10.1016\/s0735-1097(01)01795-8","journal-title":"J Am Coll Cardiol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2014.10.001","article-title":"Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations","volume":"57","author":"Gielen S","year":"2015","unstructured":"Gielen S, Laughlin MH, O'Conner C, Duncker DJ. Exercise training in patients with heart disease: review of beneficial effects and clinical recommendations. Prog Cardiovasc Dis. 2015, 57:347-55. 10.1016\/j.pcad.2014.10.001","journal-title":"Prog Cardiovasc Dis"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.08.006","article-title":"Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis","volume":"1","author":"Ismail H","year":"2013","unstructured":"Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2013, 1:514-22. 10.1016\/j.jchf.2013.08.006","journal-title":"JACC Heart Fail"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003331.pub5","article-title":"Exercise-based cardiac rehabilitation for adults with heart failure","volume":"1","author":"Long L","year":"2019","unstructured":"Long L, Mordi IR, Bridges C, et al.. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019, 1:CD003331. 10.1002\/14651858.CD003331.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003331.pub4","article-title":"Exercise-based rehabilitation for heart failure","volume":"2014","author":"Taylor RS","year":"2014","unstructured":"Taylor RS, Sagar VA, Davies EJ, et al.. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014, 2014:CD003331. 10.1002\/14651858.CD003331.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319854140","article-title":"Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis","volume":"27","author":"Bjarnason-Wehrens B","year":"2020","unstructured":"Bjarnason-Wehrens B, Nebel R, Jensen K, et al.. Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: the Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): a systematic review and meta-analysis. Eur J Prev Cardiol. 2020, 27:929-52. 10.1177\/2047487319854140","journal-title":"Eur J Prev Cardiol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2018.08.006","article-title":"Meta-analysis of exercise training on left ventricular ejection fraction in heart failure with reduced ejection fraction: a 10-year update","volume":"62","author":"Tucker WJ","year":"2019","unstructured":"Tucker WJ, Beaudry RI, Liang Y, et al.. Meta-analysis of exercise training on left ventricular ejection fraction in heart failure with reduced ejection fraction: a 10-year update. Prog Cardiovasc Dis. 2019, 62:163-71. 10.1016\/j.pcad.2018.08.006","journal-title":"Prog Cardiovasc Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022924","article-title":"High-intensity interval training in patients with heart failure with reduced ejection fraction","volume":"135","author":"Ellingsen \u00d8","year":"2017","unstructured":"Ellingsen \u00d8, Halle M, Conraads V, et al.. High-intensity interval training in patients with heart failure with reduced ejection fraction. Circulation. 2017, 135:839-49. 10.1161\/CIRCULATIONAHA.116.022924","journal-title":"Circulation"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis","volume":"3","author":"Prins KW","year":"2015","unstructured":"Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2015, 3:647-53. 10.1016\/j.jchf.2015.03.008","journal-title":"JACC Heart Fail"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-016-1014-9","article-title":"BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure","volume":"105","author":"Mir\u00f3 \u00d2","year":"2016","unstructured":"Mir\u00f3 \u00d2, M\u00fcller C, Mart\u00edn-S\u00e1nchez FJ, et al.. BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure. Clin Res Cardiol. 2016, 105:1021-9. 10.1007\/s00392-016-1014-9","journal-title":"Clin Res Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184403-the-pathophysiology-and-new-advancements-in-the-pharmacologic-and-exercise-based-management-of-heart-failure-with-reduced-ejection-fraction-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:30Z","timestamp":1707509310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184403-the-pathophysiology-and-new-advancements-in-the-pharmacologic-and-exercise-based-management-of-heart-failure-with-reduced-ejection-fraction-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":71,"URL":"https:\/\/doi.org\/10.7759\/cureus.45719","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}